Randomized Comparison of Tazarotene 0.1% Cream and Adapalene 0.3% Gel in Patients With At Least Moderate Facial Acne Vulgaris and Postinflammatory Hyperpigmentation (PIH)

Emil Tanghetti,1,4 Pamela Barnett,2 Nicolas La Gailletiére1

1Center for Dermatology and Laser Surgery, Sacramento, CA; 2Center for Dermatology, University of California, Davis, CA; 3Allergan, Inc., Irvine, CA; 4Ethica Clinical Research Inc., Montreal, QC, Canada

INTRODUCTION

Topical retinoids are frequently used for the treatment of acne because they effectively reduce the number of comedones and inflammatory acne lesions1-5. A 0.1% tazarotene cream was used in patients with PIH in a randomized, investigator-blinded, placebo-controlled study to evaluate the effects of tazarotene cream compared with placebo on the improvement of PIH and tolerability in patients with acne vulgaris.1

METHODS AND RESULTS

We have performed a randomized, investigator-blinded, placebo-controlled study to evaluate the effects of tazarotene cream compared with placebo on the improvement of PIH and tolerability in patients with acne vulgaris.1

RESULTS

The analysis of variance (ANOVA) showed a statistically significant difference between the tazarotene cream group and the placebo group. A 0.1% tazarotene cream was used in patients with PIH in a randomized, investigator-blinded, placebo-controlled study to evaluate the effects of tazarotene cream compared with placebo on the improvement of PIH and tolerability in patients with acne vulgaris.1

CONCLUSIONS

In this study, tazarotene 0.1% cream was significantly more effective than adapalene 0.3% gel in the treatment of PIH in patients with at least moderate acne.

REFERENCES


ACKNOWLEDGEMENTS

The authors thank the investigators and patients who participated in the trial. The authors also thank the staff at the trial site who contributed to the conduct of the study. The authors also thank the staff at the trial site who contributed to the conduct of the study.

Presented at: MauiDerm 2010; January 23-27, 2010; Maui, HI.


